These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10388204)

  • 1. 'Manacled competition': market reforms in German health care.
    Brown LD; Amelung VE
    Health Aff (Millwood); 1999; 18(3):76-91. PubMed ID: 10388204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market-oriented health care reforms and policy learning in the Netherlands.
    Helderman JK; Schut FT; van der Grinten TE; van de Ven WP
    J Health Polit Policy Law; 2005; 30(1-2):189-209. PubMed ID: 15943393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Mangled competition' and 'managed whatever'.
    Reinhardt UE
    Health Aff (Millwood); 1999; 18(3):92-4. PubMed ID: 10388205
    [No Abstract]   [Full Text] [Related]  

  • 4. A study on decentralizing from acute care to home care settings in Germany.
    Wasem J
    Health Policy; 1997 Sep; 41 Suppl():S109-29. PubMed ID: 10174468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switzerland.
    Zweifel P
    J Health Polit Policy Law; 2000 Oct; 25(5):937-44. PubMed ID: 11068738
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of the labor market on German health care reforms.
    Stock S; Redaelli M; Lauterbach KW
    Health Aff (Millwood); 2006; 25(4):1143-52. PubMed ID: 16835197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targets and systems of health care cost control.
    White J
    J Health Polit Policy Law; 1999 Aug; 24(4):653-96. PubMed ID: 10503152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managed competition and consumer price sensitivity in social health insurance.
    Schut FT; Hassink WH
    J Health Econ; 2002 Nov; 21(6):1009-29. PubMed ID: 12475123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citizens or shoppers? Solidarity under siege.
    Morone JA
    J Health Polit Policy Law; 2000 Oct; 25(5):959-68. PubMed ID: 11068741
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing the health care market in developing countries: prospects and problems.
    Broomberg J
    Health Policy Plan; 1994 Sep; 9(3):237-51. PubMed ID: 10137740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The marginal success of regulated competition policy in the Netherlands.
    Lieverdink H
    Soc Sci Med; 2001 Apr; 52(8):1183-94. PubMed ID: 11281402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care reform: managed competition and beyond.
    Custer W
    EBRI Issue Brief; 1993 Mar; (135):1-33. PubMed ID: 10129612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On values and democratic policy making: the deceptively fragile consensus around market-oriented medical care.
    Schlesinger M
    J Health Polit Policy Law; 2002 Dec; 27(6):889-925. PubMed ID: 12556021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care reform in The Netherlands: balancing corporatism, etatism, and market mechanisms.
    Schut FT
    J Health Polit Policy Law; 1995; 20(3):615-52. PubMed ID: 8530770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managed competition in the Netherlands: still work-in-progress.
    Van de Ven WP; Schut FT
    Health Econ; 2009 Mar; 18(3):253-5. PubMed ID: 19206093
    [No Abstract]   [Full Text] [Related]  

  • 17. Healthcare reforms and cost reduction strategies in Europe: the cases of Germany, UK, Switzerland, Italy and France.
    Simonet D
    Int J Health Care Qual Assur; 2010; 23(5):470-88. PubMed ID: 20845678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.
    Pendzialek JB; Danner M; Simic D; Stock S
    Health Policy; 2015 May; 119(5):654-63. PubMed ID: 25670009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Notes on the planned German health fund model].
    Robra BP; Mayrhofer T
    Gesundheitswesen; 2006 Oct; 68(10):650-2. PubMed ID: 17099827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cost and utilization of pharmaceuticals in Germany.
    von der Schulenburg JM
    Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.